B A R O S
Skip to main content

Baros Surgery

Procedure Overview

  • PROCEDURE TYPE: Restrictive Metabolic Surgery
  • TECHNICAL APPROACH: Laparoscopy / SILS / Robotic
  • SURGERY DURATION: 40–50 Minutes
  • FULL RECOVERY: 3–4 Weeks
  • WEIGHT LOSS: 65–80% Excess Weight
  • COMORBIDITY RESOLUTION: 60–80%
Bariatric Surgery

The Gold Standard in Bariatric And Metabolic Surgery

Roux-en-Y Gastric Bypass is widely considered the gold standard in bariatric and metabolic surgery. The procedure creates a small stomach pouch roughly the size of an egg and reroutes a section of the small intestine, combining restriction with malabsorption to achieve superior weight loss results and metabolic improvement.

RYGB is particularly effective for patients with Type 2 diabetes and those who tend toward sweet or calorie-dense foods. By bypassing the duodenum and upper jejunum, the procedure triggers powerful hormonal changes that curb appetite and improve insulin sensitivity, often resolving diabetes within weeks of surgery.

01. Who It's For

RYGB is recommended for patients with significant obesity and associated metabolic conditions, particularly those who have not achieved lasting results through diet, exercise, or less invasive procedures.

  • BMI greater than 30 with obesity-related co-morbidities
  • Patients who are 30+ kg overweight with metabolic syndrome
  • Sweet eaters and heavy calorie consumers
  • Patients with uncontrolled Type 2 diabetes or hypertension

02. How It Works

The Baros surgical team performs RYGB through a combination of restriction, malabsorption, and hormonal modification — three mechanisms working together for optimal outcomes.

03. Expected Outcomes

RYGB consistently delivers among the best long-term outcomes of any bariatric procedure. Patients at Baros Apollo can expect:

  • 65–80% excess weight loss sustained over the long term
  • Rapid improvement in Type 2 diabetes and insulin resistance
  • Reduced blood pressure, cholesterol, and cardiovascular risk
  • Resolution of 60–80% of obesity-related comorbidities